Anemia management in chronic kidney disease: What have we learned after 17 years?

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 269-272

  Spiegel, David M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 33746237598     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00171.x     Document Type: Review

References (28)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JS: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
2. Berns JS: Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Semin Dial 18:22-29, 2005
3. Center for Medicare and Medicaid Services: 2004 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Am J Kidney Dis 46:S1-S100, 2005
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
5. Li S, Collins AJ: Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65:626-633, 2004
6. Collins A: The hemoglobin link to adverse outcomes. Adv Stud Med 3:S194-S197, 2003
7. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-1507, 2003
8. Al-Ahmad R, Rand W, Manjunath G, Konstam MA, Salem DM, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955-962, 2001
9. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int 64:610-615, 2003
10. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI: Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68:2323-2330, 2005
11. Fishbane S: Anemia, chronic kidney disease, and cardiovascular disease: the clinical trials. Adv Stud Med 5:S715-S719, 2005
12. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J: Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 57:1086-1095, 2004
13. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44:866-876, 2004
14. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
15. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353-361, 2003
16. Strippoli GF, Craig JC, Manno C, Schena FP: Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 15:3154-3165, 2004
17. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 15:148-156, 2004
18. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46:799-811, 2005
19. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180-2189, 2005
20. MacDougall IC, Steering Committee of the CREATE trial, CREATE Study Group: New strategies for earl anaemia management in renal insufficiency. Nephrol Dial Transplant 18(suppl 2):ii13-ii16, 2003
21. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA: Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149:408-413, 2005
22. Jones M, Ibels L, Schenkel B, Zagari M: Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 65:757-767, 2004
23. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64:1514-1521, 2003
24. Brier ME, Aronoff GR: Hemoglobin goals and the natural variability in the erythropoietin response. J Am Soc Nephrol 13:628A, 2002
25. Krishnan M, Adams E: Operationalizing anemia management: organizing the program and coordinating the team. Nephrol Nurs J 30:567-570, 2003
26. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46:481-488, 2005
27. Martin Guerrero JD, Soria Olivas E, Camps Valls G, Serrano Lopez AJ, Perez Ruixo JJ, Jimenez Torres NV: Use of neural networks for dosage individualization of erythropoietin in patients with secondary anemia to chronic renal failure. Comput Biol Med 33:361-373, 2003
28. Spiegel DM, Chonchol M, Bispham B, Dwight C, Smith M: Improving anemia management using a computerized rHuEPO dosing algorithm. J Am Soc Nephrol 13:220A, 2002